Atara Biotherapeutics (ATRA) FCF Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly FCF Margin came in at 595.54% in Q1 2026, down 56687.0% YoY from N/an in Q1 2025, and down 66.74% on a QoQ basis from 357.18% in Q4 2025.
Atara Biotherapeutics (ATRA) FCF Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 6 years of FCF Margin data on file, last reported at 595.54% in Q1 2026.
- Quarterly FCF Margin fell 56687.0% year-over-year to 595.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 111.82% (down 7803.0% YoY) and the FY2025 annual result came in at 42.18%, up 1131.0% from the prior year.
- FCF Margin slipped to 595.54% in Q1 2026, from 357.18% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 1600.8% in Q4 2023 to a low of 32621.95% in Q2 2023.
- A 5-year average of 2766.81% and a median of 201.33% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin plunged 3250273 bps — and 2024, when it jumped 3258424 bps.
- Tracing ATRA's FCF Margin over 5 years: stood at 3209.59% in 2022, then jumped by 150 bps to 1600.8% in 2023, then slumped by 105 bps to 74.99% in 2024, then tumbled by 376 bps to 357.18% in 2025, then slumped by 67 bps to 595.54% in 2026.
- The last three FCF Margin figures came in at 595.54% (Q1 2026), 357.18% (Q4 2025), and 283.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 70.82% |
| 10 | Atara Biotherapeutics | 142.96 Mn | 126.41 Mn | 439,000.00 | -529.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -529.84% |
| Mar 31, 2026 | -595.54% |
| Dec 31, 2025 | -357.18% |
| Sep 30, 2025 | -283.43% |
| Jun 30, 2025 | -41.64% |
| Mar 31, 2025 | -28.67% |
| Dec 31, 2024 | -74.99% |
| Sep 30, 2024 | -9.93% |
| Jun 30, 2024 | -37.71% |
| Mar 31, 2024 | -108.24% |
| Dec 31, 2023 | 1,600.80% |
| Sep 30, 2023 | -2,555.79% |
| Jun 30, 2023 | -32,621.95% |
| Mar 31, 2023 | -4,369.12% |
| Dec 31, 2022 | -3,209.59% |
| Sep 30, 2022 | -1,456.83% |
| Jun 30, 2022 | -119.22% |
| Dec 31, 2021 | -457.74% |
| Sep 30, 2021 | -1,053.59% |
| Jun 30, 2021 | -1,644.39% |